Lantern Pharma Inc (NASDAQ:LTRN) progresses with clinical trials for cancer therapies and advances in AI-driven drug development.
Financial discipline emphasized with a cash runway into at least Q3 of 2025, backed by approximately $45 million in cash and securities.
Operational highlights include IND clearance for LP-284, dosing of initial patient in LP-184 Phase 1 trial, and progression of LP-300 Harmonic clinical trial.
Company's RADR AI platform continues to evolve, enhancing the prediction of drug-cancer interactions and development of ADCs.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.